Literature DB >> 12114404

Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma.

Hilde Dannenberg1, Winand N M Dinjens, Mustaffa Abbou, Hero Van Urk, Bernard K H Pauw, Diane Mouwen, Wolter J Mooi, Ronald R de Krijger.   

Abstract

PURPOSE: Recently, familial paraganglioma (PGL) was shown to be caused bymutations in the gene encoding succinate dehydrogenase subunit D (SDHD). However, the prevalence of SDHD mutations in apparently sporadic PGL is unknown. We studied the frequency and spectrum of germ-line and somatic SDHD mutations in patients with parasympathetic PGL. EXPERIMENTAL DESIGH: We studied 57 unselected patients who developed parasympathetic PGLs (n = 105 tumors) and who were treated between 1987 and 1999 at the Erasmus MC (Rotterdam, the Netherlands). Thirty-eight (67%) of these patients (n = 51 tumors) lacked a family history of parasympathetic PGL. We used conformation-dependent gel electrophoresis and sequence determination analysis of germ-line and tumor DNA to identify SDHD mutations. We compared the clinical and molecular characteristics of sporadic and hereditary PGLs.
RESULTS: Three different SDHD germ-line mutations were identified in 32 of the 57 (56%) patients. These included 19 of 19 (100%) patients with familial PGL and also 13 of 38 (34%) patients with apparently sporadic PGL. All three mutations were characterized as missense mutations (D92Y, L95P, and L139P) in highly conserved regions of the SDHD gene and were not observed in 200 control alleles. No somatic mutations were found.
CONCLUSIONS: Germ-line mutations of the SDHD gene are present in a significant number of patients with apparently sporadic parasympathetic PGL. Somatic SDHD mutations do not play a significant role in the sporadic form of this tumor. Genetic testing for SDHD germ-line mutations should be considered for every patient presenting with this tumor, even if a personal or family history of PGL is absent, to allow appropriate clinical management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114404

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.

Authors:  Dorian R A Swarts; Sandra M H Claessen; Yvonne M H Jonkers; Robert-Jan van Suylen; Anne-Marie C Dingemans; Wouter W de Herder; Ronald R de Krijger; Egbert F Smit; Frederik B J M Thunnissen; Cornelis A Seldenrijk; Aryan Vink; Aurel Perren; Frans C S Ramaekers; Ernst-Jan M Speel
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

Review 2.  Mutations of the SDHB and SDHD genes.

Authors:  Christian Pawlu; Birke Bausch; Hartmut P H Neumann
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Cervical paragangliomas: is SDH genetic analysis systematically required?

Authors:  Nicolas Fakhry; Patricia Niccoli-Sire; Anne Barlier-Seti; Roch Giorgi; Antoine Giovanni; Michel Zanaret
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-07       Impact factor: 2.503

4.  Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1.

Authors:  Mariola Peczkowska; Zoran Erlic; Michael M Hoffmann; Mariusz Furmanek; Jaroslaw Cwikla; Agata Kubaszek; Aleksander Prejbisz; Zbigniew Szutkowski; Andrzej Kawecki; Krzysztof Chojnowski; Anna Lewczuk; Mieczyslaw Litwin; Witold Szyfter; Martin A Walter; Maren Sullivan; Charis Eng; Andrzej Januszewicz; Hartmut P H Neumann
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

Review 5.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.

Authors:  Francien H van Nederveen; José Gaal; Judith Favier; Esther Korpershoek; Rogier A Oldenburg; Elly M C A de Bruyn; Hein F B M Sleddens; Pieter Derkx; Julie Rivière; Hilde Dannenberg; Bart-Jeroen Petri; Paul Komminoth; Karel Pacak; Wim C J Hop; Patrick J Pollard; Massimo Mannelli; Jean-Pierre Bayley; Aurel Perren; Stephan Niemann; Albert A Verhofstad; Adriaan P de Bruïne; Eamonn R Maher; Frédérique Tissier; Tchao Méatchi; Cécile Badoual; Jérôme Bertherat; Laurence Amar; Despoina Alataki; Eric Van Marck; Francesco Ferrau; Jerney François; Wouter W de Herder; Mark-Paul F M Vrancken Peeters; Anne van Linge; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Ronald R de Krijger; Winand N M Dinjens
Journal:  Lancet Oncol       Date:  2009-07-01       Impact factor: 41.316

7.  Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect.

Authors:  Kristin Astrom; Joel E Cohen; Joan E Willett-Brozick; Christopher E Aston; Bora E Baysal
Journal:  Hum Genet       Date:  2003-06-17       Impact factor: 4.132

Review 8.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

9.  Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.

Authors:  Jean-Pierre Bayley; Ivonne van Minderhout; Marjan M Weiss; Jeroen C Jansen; Peter H N Oomen; Fred H Menko; Barbara Pasini; Barbara Ferrando; Nora Wong; Lesley C Alpert; Rosie Williams; Edward Blair; Peter Devilee; Peter E M Taschner
Journal:  BMC Med Genet       Date:  2006-01-11       Impact factor: 2.103

10.  Genetic Variants in Patients with Multiple Head and Neck Paragangliomas: Dilemma in Management.

Authors:  Anasuya Guha; Ales Vicha; Tomas Zelinka; Zdenek Musil; Martin Chovanec
Journal:  Biomedicines       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.